Abstract
SHIP (SH2 domain containing inositol phosphatases) was identified as a 145kDa multi-domain cytosolic protein expressed specifically in hematopoietic cells that negatively regulates cell growth, survival and proliferation. Aberrant SHIP function is associated with many disease pathologies. There are two aspects to SHIP function: the catalytic function mediated by the central catalytic domain and the non-catalytic function mediated by the protein-protein interaction domains of SHIP. Much is known about the catalytic function of SHIP and its role in regulation of growth factor and immune receptor signaling. However, not much is known about the mechanistic details of the non-catalytic functions of SHIP and this is an active area of research. In this review, we discuss the role of SHIP in different cell types of immune system, its role in various diseases and its potential as a therapeutic target.
Keywords: SH2 domain, SH3 domain, SHIP, catalytic and non-catalytic function of SHIP, PI3K, SHIP-deficient, innate and adaptive immunity
Current Enzyme Inhibition
Title: Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Volume: 5 Issue: 3
Author(s): Payal Mehta, Jonathan P. Butchar and Susheela Tridandapani
Affiliation:
Keywords: SH2 domain, SH3 domain, SHIP, catalytic and non-catalytic function of SHIP, PI3K, SHIP-deficient, innate and adaptive immunity
Abstract: SHIP (SH2 domain containing inositol phosphatases) was identified as a 145kDa multi-domain cytosolic protein expressed specifically in hematopoietic cells that negatively regulates cell growth, survival and proliferation. Aberrant SHIP function is associated with many disease pathologies. There are two aspects to SHIP function: the catalytic function mediated by the central catalytic domain and the non-catalytic function mediated by the protein-protein interaction domains of SHIP. Much is known about the catalytic function of SHIP and its role in regulation of growth factor and immune receptor signaling. However, not much is known about the mechanistic details of the non-catalytic functions of SHIP and this is an active area of research. In this review, we discuss the role of SHIP in different cell types of immune system, its role in various diseases and its potential as a therapeutic target.
Export Options
About this article
Cite this article as:
Mehta Payal, Butchar P. Jonathan and Tridandapani Susheela, Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy, Current Enzyme Inhibition 2009; 5 (3) . https://dx.doi.org/10.2174/157340809789071182
DOI https://dx.doi.org/10.2174/157340809789071182 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potentiating Effect of Ethnomedicinal Plants Against Proliferation on Different Cancer Cell Lines
Current Drug Metabolism Quercetin and MicroRNA Interplay in Apoptosis Regulation in Ovarian Cancer
Current Pharmaceutical Design Signaling in Human B-Lymphoma Rafts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation
Current Pharmaceutical Biotechnology Stereoselective Metabolic and Pharmacokinetic Analysis of the Chiral Active Components from Herbal Medicines
Current Pharmaceutical Analysis Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inhibition of DNA Polymerase λ Suppresses 12-O-Tetradecanoylphorbol- 13-Acetate-Induced Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Current Pharmaceutical Biotechnology Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry Heterocyclic Analogues as Kinase Inhibitors: A Focus Review
Current Topics in Medicinal Chemistry